1,6-Naphthyridine-3-carboxamide,4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-；BAY 94-8862
CAS:1050477-31-0
Chemical Formula:C21H22N4O3
MW:378.42
Availability: R&D; Commercialization
⬤ CAS No.1050477-31-0
⬤ Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| English Name | Finerenone |
| CAS No. | 1050477-31-0 |
| Chemical Formula | C21H22N4O3 |
| Molecular Weight | 378.42 |
| Related Categories | Finerenone intermediates |
| Mol | 1050477-31-0.mol |
| Boiling point | 554.7±50.0 °C(Predicted) |
| Density | 1.29±0.1 g/cm3(Predicted) |
| Storage conditions | -20°C |
| Solubility | DMF: 10 mg/ml DMSO: 3 mg/ml Ethanol: insol PBS (pH 7.2): insol |
| Acidity coefficient (pKa) | 14.76±0.40(Predicted) |
| Form | Solid |
| Color | White to off-white |
| Maximum wavelength (λmax) | 255 nm |
| Adverse Reactions | Common: Dizziness, fatigue, hypotension, hypokalemia (low potassium levels) |
| Less common: Gastrointestinal irritation, allergic reactions, renal impairment | |
| Drug Interactions | May interact with CYP3A4 inhibitors, increasing the risk of adverse effects |
| Monitoring | Regular monitoring of potassium levels and renal function recommended |
| Special Populations | Elderly patients may not require dose adjustment; caution in patients with hepatic or renal impairment |
| Introduction | Finerenone is a novel mineralocorticoid receptor antagonist that has the effect of delaying the progression of chronic kidney disease. |
| Uses | Finerenone is the first non-steroidal selective mineralocorticoid receptor antagonist, which can be used to treat diabetic nephropathy, chronic kidney disease and end-stage renal disease, and can reduce proteinuria and improve glomerular filtration rate in patients. |
| Biological Activity | Finerenone (FIN, BAY94-8862) is a highly selective, orally active non-steroidal antagonist of mineralocorticoid receptor (MR) with an IC50 value of 18nM. Finerenone has the potential to study cardiorenal diseases such as type 2 diabetes and chronic kidney disease. |
Exceptional Product Quality
“We have been sourcing pharmaceuticals from Tianming Pharmaceutical for several years now, and their product quality has consistently exceeded our expectations. Each batch undergoes rigorous testing, ensuring we receive only the highest quality products. This reliability has significantly contributed to our trust and satisfaction with their services. Highly recommended!”
June 15, 2023
Outstanding Technical Guidance
“The technical guidance provided by Tianming Pharmaceutical’s team has been invaluable to our research and development projects. Their experts are knowledgeable, responsive, and always willing to assist with detailed explanations and support. Their guidance has enabled us to optimize our processes and achieve remarkable results. We couldn’t ask for a better partner.”
June 15, 2023
Superior Service Experience
“Our experience with Tianming Pharmaceutical has been nothing short of excellent. Their customer service team is exceptionally responsive and dedicated to meeting our needs. From initial consultation to after-sales support, they have provided seamless, professional service. Their commitment to customer satisfaction is truly commendable.”
June 15, 2023
Precise Product Specifications
“Tianming Pharmaceutical has impressed us with their adherence to precise product specifications. Each order is meticulously packaged and delivered exactly as requested, ensuring that we receive products that perfectly meet our requirements. Their attention to detail and commitment to accuracy have made them a trusted supplier for our business.”
June 15, 2023
Finerenone vs spironolactone: head-to-head real-world data shows finerenone has 69% lower mortality, 53% fewer kidney events, and less hyperkalemia. Nonsteroidal MRA with no hormonal side effects.
Clascoterone for hair loss: Phase 3 trials show significant regrowth with minimal systemic absorption. How it works, side effects, and comparison to finasteride.
Does GLP-1 cause hair loss? Yes, studies on 1.1M+ patients show an association—driven by rapid weight loss, not direct drug toxicity. Telogen effluvium is temporary. New oral drug Foundayo (orforglipron) included.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.
